Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 26 points (0.2%) at 17,168 as of Friday, Oct. 16, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,423 issues advancing vs. 1,539 declining with 158 unchanged.

The Health Care sector currently sits down 0.4% versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the sector include Cempra ( CEMP), down 30.6%, Vertex Pharmaceuticals ( VRTX), down 1.9%, Regeneron Pharmaceuticals ( REGN), down 1.6% and Amgen ( AMGN), down 0.9%. Top gainers within the sector include Valeant Pharmaceuticals International ( VRX), up 4.1%, Novo Nordisk A/S ( NVO), up 3.2%, Edwards Lifesciences ( EW), up 2.0%, Express Scripts ( ESRX), up 1.6% and Eli Lilly and ( LLY), up 1.3%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Incyte ( INCY) is one of the companies pushing the Health Care sector lower today. As of noon trading, Incyte is down $5.50 (-4.9%) to $107.02 on average volume. Thus far, 1.1 million shares of Incyte exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $106.75-$112.28 after having opened the day at $111.72 as compared to the previous trading day's close of $112.52.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. Incyte has a market cap of $19.1 billion and is part of the drugs industry. Shares are up 44.9% year-to-date as of the close of trading on Thursday. Currently there are 10 analysts that rate Incyte a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Incyte as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including poor profit margins and generally higher debt management risk. Get the full Incyte Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Alexion Pharmaceuticals ( ALXN) is down $2.19 (-1.4%) to $158.88 on light volume. Thus far, 636,463 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $158.59-$163.28 after having opened the day at $161.96 as compared to the previous trading day's close of $161.07.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $34.5 billion and is part of the drugs industry. Shares are down 17.5% year-to-date as of the close of trading on Thursday. Currently there are 13 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in net income and good cash flow from operations. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Alexion Pharmaceuticals Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Illumina ( ILMN) is down $3.03 (-2.0%) to $148.81 on light volume. Thus far, 681,092 shares of Illumina exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $148.44-$152.80 after having opened the day at $152.00 as compared to the previous trading day's close of $151.84.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $20.9 billion and is part of the drugs industry. Shares are down 21.7% year-to-date as of the close of trading on Thursday. Currently there are 11 analysts that rate Illumina a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Illumina Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).